Jim is an Auckland-based company director who is currently the Chair of Aroa Biosurgery Ltd., Prevar Ltd., Infotools Ltd.,and Pictor Ltd., Mr McLean was previously an Executive Director of Genesis Research and prior to that, a partner with Ernst & Young. He is a Member of the Institute of Directors and is an Associate Chartered Accountant.
Non Executive Director
Phil holds a Bachelor of Business Studies from Massey University majoring in Accounting, Finance and Information Technology. Phil qualified as a chartered accountant and was a member of the New Zealand Society of Accountants from 1991 through to 1998. Phil has served on the Boards of numerous early stage companies since 1997.
Brian has held senior corporate roles in life sciences and health care companies over the last 20 years. He is a graduate from Massey University with a Bachelors degree in Veterinary Science, a Member of the Royal College of Veterinary Surgeons (UK), and holds a Masters degree in Business Administration graduating with distinction. He has extensive management experience in life science companies spanning clinical, technical, sales, marketing, corporate development and strategy having worked for a number of multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, has sat on a number of government and industry expert panels and is a member of the Massey University Foundation and Equine Research Boards.
John has over 26 years of global leadership experience in biotechnology, pharmaceutical, combination products and
device industries. He is currently Senior Vice President, Global Quality & Compliance at Roche and was previously at Genentech and Baxter. He has had leadership roles in Quality & Compliance, Manufacturing and Engineering living and working in multiple regions including North America, Europe and Asia.
Steve Engle brings deep experience in US capital markets, a record of achievement with big pharma partnering and established links with the US FDA. As a former CEO of NASDAQ-listed companies Xoma and La Jolla Pharmaceuticals, he brings wide networks in the US and European biotech industries. He is a current CEO of Averigon Consulting, a leading advisory firm to the US life sciences industry.